Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
"Epidemiology, Approaches to the Diagnosis and Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
1 other identifier
observational
1
1 country
1
Brief Summary
In connection with the transition to the 8th version of the classification of lung cancer according to the TNM system, there are currently no precise epidemiological data on stage III NSCLC, clinical characteristics of patients in this group, approaches to therapy and treatment results in the Russian Federation. The published statistics only provide information on the overall incidence of stage III lung, trachea and bronchial cancer, which is about 40%. This observational study will make it possible to characterize the Russian population of stage III non-small cell lung cancer patients, approaches to choosing a treatment option for stage III NSCLC and the outcomes of this treatment in real clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 10, 2020
CompletedFirst Submitted
Initial submission to the registry
September 21, 2020
CompletedFirst Posted
Study publicly available on registry
December 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2023
CompletedDecember 15, 2021
December 1, 2021
3 years
September 21, 2020
December 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Examine clinical and morphological groups
* gender ratio (husband, wife) * smoking status (smoker, non-smoker, past smoker) * proportional distribution: squamous cell, adenocarcinoma, dimorphic cancer, others) * how many patients with mediastinal lymph node involvement: (N0, N1, N2, N3) * detection frequency: PDL (PDL \<1, PDL\> 1, PDL \<49, PDL\> 50), EGFR (EGFR + (19.24 exon) EGFR-), (ALK +, ALK -), (ROS-1 +, ROS-1 -) Get information about regional algorithms * Variants of treatment tactics: Percentage: a. Surgery v. Chemotherapy -Diagnostic algorithm: a. Morphological verification frequency b. The frequency of confirmation of metastatic lesions within the thoracic lymph nodes c. F
10/01/2023
Secondary Outcomes (3)
Explore clinical approaches
10/01/2023
Diagnostic algorithm:
10/01/2023
Percentage of treatment options
10/01/2023
Other Outcomes (1)
-Evaluate the frequency of decision-making as a standard practice vs with an individual decision
10/01/2023
Eligibility Criteria
patients with morphologically proven stage III non-small cell lung cancer
You may qualify if:
- \- stage III non-small cell lung cancer
You may not qualify if:
- \- the rest of the disease stage
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Medical Research Center of Oncology. N. N. Blokhin
Moscow, 115478, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 21, 2020
First Posted
December 15, 2021
Study Start
January 10, 2020
Primary Completion
January 15, 2023
Study Completion
March 31, 2023
Last Updated
December 15, 2021
Record last verified: 2021-12